News
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...
Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...
Eli Lilly (LLY) stock in focus as the company launches Mounjaro Kwikpen in India, intensifying competition with Novo ...
Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets ...
Eli Lilly (LLY) launched an injector pen for Mounjaro, its weight-loss drug, for 14,000 rupees, or $160, for its starting dose in India, Rishika ...
1don MSN
Why Eli Lilly Stock Popped Today
Eli Lilly is now selling Mounjaro GLP-1 weight loss drugs in India. Rival Novo Nordisk began Indian Wegovy sales in June. Lilly is underpricing its rival in the Indian weight loss market.
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback